Nektar (NKTR) Data Shows Single-Agent NKTR-214 Produces Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity
Tweet Send to a Friend
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for NKTR-214, an immuno-stimulatory CD-122 biased cytokine currently being evaluated in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
